LCTX - Lineage Cell Therapeutics, Inc. Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Lineage Cell Therapeutics (LCTX) product diversification via its eye and nervous system treatment platform minimizes the risks of failed trials. This price chart confirms the strategy's effectiveness, with the EV/EBITDA ratio standing at 0.00. The business relies on US tissue and vision regeneration centers. The current development vector is based on scaling retinal therapy and strengthening partnerships with industry behemoths.

LCTX Lineage Cell Therapeutics Inc: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization in the range 11/23/2025 - 11/11/2026

lineagecell.com - analytical breakdowns and key metrics (LCTX)

- market price and analyst price targets:

Price Chart Lineage Bio|LCTX - Price Target Chart

- market capitalization statistics:

Market Value Lineage Corp|LCTX - Company Buyout Price

- book value of equity indicators:

Net Assets per Single Share Lineage Cell Therapeutics|LCTX - Company Book Value|Market Capitalization to Book Value Ratio lineagecell.com|LCTX - Company Total Asset Base

- company liabilities and liquidity data:

- business earnings and investment ratios data:

LCTX - Company Net Income|Future Profit Lineage Cell Therapeutics|LCTX - Company Value to Net Income|Forward P/E Multiple Lineage Cell Therapeutics|LCTX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Lineage Corp|LCTX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Lineage Cell Therapeutics|LCTX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lineagecell.com|LCTX - Earnings per share growth in current year|Expected earnings per share growth for next year Lineage Cell Therapeutics

Initial company analysis:Lineage Bio LCTX

The EV/EBITDA multiple measures the total value of a business, including net debt, relative to operating profit before interest, taxes, depreciation, and amortization. Investors utilize this calculation to determine an asset's market premium compared to industry peers. By analyzing the EV/EBITDA chart, one can identify price overheating or potential undervaluation. For Lineage Cell Therapeutics (LCTX), this indicator reflects the value of its leadership in regenerative medicine and the development of irreplaceable treatments for paralysis.

Competitors of Lineage Cell Therapeutics

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mesoblast Corp MESO|Surrozen Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CCEL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio FibroBiologics, Inc. FBLG|Longeveron (LGVN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BRTX (BioRestorative Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CELZ (Creative Medical Technology Holdings, Inc.) - EV/EBITDA Multiple